The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Eli Lilly stock jumps more than 10% as Mounjaro, Zepbound sales surge

Nov 3, 2026 03:03 (1h ago)

Verifying

Eli Lilly reported strong third-quarter results and raised its 2026 revenue outlook.
Mounjaro and Zepbound generated combined quarterly sales of $16.1 billion.
Lilly's Dec. 7 Investment Community Meeting will present its drug pipeline.